Expanded Supply Options for the Clinical Diagnostics Industry Labmate Online


Biosynth Carbosynth, a global supplier of critical materials to the life sciences industry, has acquired Aalto Bio Reagents (Dublin), a leading developer and supplier of biological materials for the in vitro diagnostics (IVD) and vaccine development industries in the emerging emerging arena Diseases.

dr Urs Spitz, CEO and President of Staad-based Biosynth, said: “This acquisition marks the next phase on our ambitious journey to become a global leader and partner to the biopharmaceutical and diagnostics industries. This enables us to offer our IVD customers an expanded range of products, including complex biochemicals, peptides and biological materials. We are pleased to welcome Aalto and his staff and look forward to working with them to further expand our offering to the diagnostics industry.”

Philip Noone, CEO of Aalto, added: “We are delighted to be collaborating with Biosynth, a world-renowned provider with a broad portfolio of critical biopharmaceutical and diagnostics products and services. Aalto’s industry-leading products and focus on emerging diseases are a great fit with Biosynth’s products, and we see tremendous opportunity for the platform to be at the forefront of new innovative product development and provide our customers with even greater breadth and variety of products deliver what they need to solve the diseases of the future.”

More information on-line


Comments are closed.